Prospective evAluatIon foR Inhalation Devices Study (PAIR)
Multicenter, Prospective, Observational, Non Interventional Clinical Trial to Assess the Asthma and COPD Treatment by Inhalation Devices
ASTHMA:
Asthma is a chronic inflammatory disorder of the airways in which many different types of cells, and various cellular components. The chronic inflammation causes an increase of the over-responsiveness of the airways, which leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning hours. These episodes, usually associated with widespread but variable block the airway, which is usually reversible either spontaneously or by treatment.
Asthma is one of the most common chronic diseases worldwide, posing significant social burden in both children and adults. It is estimated that about 300 million people currently suffer from asthma. The incidence of asthma is universal regardless of the level of development of the country. There is evidence that over the last 20 years the prevalence has increased significantly, specially in pediatric populations.
COPD:
Chronic Obstructive Pulmonary Disease (COPD) is a major public health problem. It is the fourth leading cause of chronic morbidity and mortality in the United States after heart disease, strokes and acute respiratory infections, while on an annual basis, the disease robs the lives of more than 3,000,000 people around us worldwide. The most worrying is that the impact has been steadily rising, and this dramatic increase in the frequency shows that by 2020 the disease will be the third leading cause of death. In Greece, 8.4% of the population suffers from COPD.
Smoking is the leading cause of COPD. However, not all smokers develop the clinical picture of COPD, suggesting that additional factors are involved in manifestation. Further investigation of risk factors for COPD, methods of reducing exposure to these agents and the molecular and cellular mechanisms involved in the pathogenesis remain a major area of research to develop effective treatments that will reduce or prevent the development the disease.
研究概览
详细说明
ASTHMA TREATMENT:
As regards the pharmacological management of asthma, inhaled corticosteroids (eg budesonide, fluticasone and beclomethasone) underlying the maintenance therapy, while beta-2 agonists are the long-term preferred additional treatment. Other common medications are systemic corticosteroids, beta-2-agonist short duration (eg salbutamol) oral beta2-agonists, long-lasting, methylxanthines, converters leukotrienes, colors and anticholinergics.
The main clinical advantages of transport and deposition of the drug directly to the lungs associated with the safety and efficacy: the side effects associated with the systemic circulation zero, while high concentrations of the active substance can be directly attributed to the points of action. Furthermore, the onset of action of inhaled beta2-agonist is faster that of oral beta-2 agonist and the therapeutic response is achieved faster. Finally, require lower doses of the drug, due to the efficiency of this direct lungs, reducing the problems of poor absorption and metabolism by the liver.
COPD TREATMENT:
Effective management of COPD involves four steps: (1) assessment and monitoring of the disease, (2) minimize the risk factors, (3) stabilization of disease, and (4) the treatment of an exacerbation.
ELPENHALER:
A new multi-single dose inhaled dry powder (Elpenhaler ®) has been designed, developed and patented by the Elpen Pharmaceutical Co. Inc (Pikermi, Greece). The new inhaler is suitable for the performance of a range of drugs for asthma, such as budesonide, formoterol and fluticasone.
OTHER TREATMENT APPROACHES:
Most asthma medications are administered in the form of inhalers. There are various forms of devices that facilitate the administration of inhaled medications in young children. The correct use of inhalers drugs is very important for the treatment of asthma. If the patient does not understand the correct instructions, the drug is deposited satisfactorily lungs, ie organ must act, so there is no remission. Furthermore when the inhalers incorrectly used much of the drug remains in the oral cavity and the pharynx and therefore the patient is exposed to any adverse events drug while not treated properly asthma. Appropriate for patient inhaler should be chosen by the attending physician, after confirmation by pilot demonstration site at the clinic, the patient (depending on age) have understood and can apply the device user. A new study conducted by the Center for Capital allergies and respiratory diseases showed that 25% of asthmatic subjects reported that the inhaler was empty during an asthma attack. The reason: "There is no way for someone to see how much medicine has used the inhaler continues to blow air even when it is empty," says Bradley Chips, who was lead author of the study. To save your breath, look at the package leaflet number of inhaled doses contain.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Athens、希腊
- Evagelismos hospital
-
Athens、希腊
- Private Office
-
Lamia、希腊
- General State hospital of Lamia
-
Piraeus、希腊
- Private Office
-
Volos、希腊
- Private Office
-
Voula、希腊
- Asklipiion Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patients (newly diagnosed or not) with asthma and / or COPD, who use correctly (according to the opinion of the responsible investigator) their device
- Male or female patients aged 18 years
- Patients with compliance to treatment
- Patients with compliance to the study procedures
- Patients who have signed the study participation consent form.
Exclusion Criteria:
- Patients who use incorrectly their inhalational devices
- Male or female patients under 18 years
- Patients who are non-compliant to their treatment for asthma and COPD
- Patients who are non-compliant to study procedures
- Patients who have not signed the study participation consent form.
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
|---|
|
asthma, COPD
patients with asthma and COPD treated with inhalation devices
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
FSI-10 score
大体时间：2 months treatment
|
FSI-10 questionnaire total score FSI-10 questionnaire score per question
|
2 months treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adverse Events Reporting
大体时间：2 months treatment
|
Number of Adverse Events occured during study duration.
|
2 months treatment
|
合作者和调查者
调查人员
- 研究主任：Spyridon Papiris, MD, Professor、Professor of Pulmonology, Attikon University Hospital of Athens
- 首席研究员：Athina Vlachou, MD、Private Office
- 首席研究员：Areti Xifteri-Nikolinati, MD、Messini, Greece
- 首席研究员：Georgios Efraimidis, MD、Plmonology Hospital of Patras, Greece
- 首席研究员：Nikolaos Harokopos, MD、General hospital of Pyrgos, Peloponnese, Greece
- 首席研究员：Dionysia Kalampoka, MD、Private Office, Patras, Greece
- 首席研究员：Athanasia Christara, MD、Private Office, Korinthos, Greece
- 首席研究员：Emmanouel Fothiantakis, MD、Private Office, Chaidari, Athens, Greece
- 首席研究员：Elias Kainis, MD、Sotiria Pulmonogy Hospital of Athens
- 首席研究员：Adamantia Liapikou, MD、Sotiria Pulmonary Hospital of Athens
- 首席研究员：Xenophon Agelidis, MD、Attikon Hospital
- 首席研究员：Antonios Kopanakis, MD、Thriasio General Hospital, Greece
- 首席研究员：Konstantina Houliara, MD、Private office, Patisia, Athens, Greece
- 首席研究员：Helen Adamou, MD、Nea Filadelfia, Athens, Greece
- 首席研究员：George Kalfountzos, MD、Private office, Larissa, Greece
- 首席研究员：Athanasios Pitenis, MD、Private Office, Grevena, Greece
- 首席研究员：Eugeneia Karyanou, MD、Private Office, Kaisariani, Athens, Greece
- 首席研究员：Georgia Kotantoula, MD、Private Office, Gerakas, Attika, Greece
- 首席研究员：Evangelos Bourantzis, MD、Private office, Athens, Greece
- 首席研究员：Konstantinos Marosis, MD、Sotiria Pulmonary Hospital of Athens
- 首席研究员：Harilaos Lambrakis, MD、Sotiria Pulmonary Hospital of Athens
- 首席研究员：Anastasios Palamidas, MD、Sotiria Pulmonary Hospital of Athens
- 首席研究员：Dimitrios Zois, MD、General Hospital of Karditsa, Greece
- 首席研究员：Maria Varouha, MD、Private office, Rethymno, Crete, Greece
- 首席研究员：Karmen Stahouli, MD、Hatzikosta Hospital of Ioannina, Greece
- 首席研究员：Peter Oikonomides, MD、General Hospital of Filiata, Thesprotia, Greece
- 首席研究员：George Balasoulis, MD、Private office, Thessaloniki, Greece
- 首席研究员：Konstantinos Porpodis, MD、Private office, Thessaloniki, Greece
- 首席研究员：Despina Melemeni, MD、Sismanogleio Hospital of Athens, Greece
- 首席研究员：Andreas Stratis, MD、Private office, Greece
- 首席研究员：Efrosini Manali, MD、Attikon University Hospital of Athens, Greece
- 首席研究员：Theodora Tsiounta, MD、Theageneio oncology hospital of Thessaloniki, Greece
- 首席研究员：Anna Gavriilidou, MD、Papageorgiou hospital of Thessaloniki, Greece
- 首席研究员：Athanasia Pataka, MD、Papanikolaou General hospital of Thessaloniki, Greece
- 首席研究员：Chrysavgi Terovitou, MD、General hospital of Kavala, Greece
- 首席研究员：Elisavet Christina Filippidou, MD、General hospital of Kavala, Greece
- 首席研究员：Paschalis Kakavelas, MD、Private office, Piraeus, Greece
- 首席研究员：Nikolaos Manolakoglou, MD、Private office, Kalamaria, Thessaloniki, Greece
- 首席研究员：Evangelia Tsikrika, MD、General hospital of Veroia, Greece
- 首席研究员：Athanasios Papandreou, MD、Private office, Orestiada, Greece
- 首席研究员：Vasilios Adamidis, MD、Private office, Kozani, Greece
- 首席研究员：Paraskevi Tsafaridou, MD、Private office, Thessaloniki, Greece
- 首席研究员：Maria Katertzi, MD、Private office, Moudania, Thessaloniki, Greece
- 首席研究员：Pashalia Tsiaga, MD、Private office, Serres, Greece
- 首席研究员：Christos Babalis, MD、Private office, Serres, Greece
- 首席研究员：Konstantinos Albantakis, MD、Private office, Larisa, Greece
- 首席研究员：Martha Andritsou, MD、Sotiria Pulmonology Hospital of Athens
出版物和有用的链接
一般刊物
- National Asthma Education and Prevention Program. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002. J Allergy Clin Immunol. 2002 Nov;110(5 Suppl):S141-219. No abstract available. Erratum In: J Allergy Clin Immunol. 2003 Mar;111(3):466.
- van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J. 1999 Nov;14(5):1034-7. doi: 10.1183/09031936.99.14510349.
- Campbell JL, Kiebert GM, Partridge MR. Development of the satisfaction with inhaled asthma treatment questionnaire. Eur Respir J. 2003 Jul;22(1):127-34. doi: 10.1183/09031936.03.00097503.
- Perpina Tordera M, Viejo JL, Sanchis J, Badia X, Cobos N, Picado C, Sobradillo V, Martinez Gonzalez del Rio J, Duce F, Munoz Cabrera L. [Assessment of patient satisfaction and preferences with inhalers in asthma with the FSI-10 Questionnaire]. Arch Bronconeumol. 2008 Jul;44(7):346-52. Spanish.
- van Beerendonk I, Mesters I, Mudde AN, Tan TD. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma. 1998;35(3):273-9. doi: 10.3109/02770909809068218.
- Reliability of the FSI-10 questionnaire for the assessment of the usability of drug inhalers in Greek patients, accepted for publication by 'Archives of Hellenic Medicine'
- Global Strategy for Asthma Management and Prevention NIH Publication No 02-3659 Issued January, 1995 (updated 2002) Management Segment (Chapter 7): Updated 2005 from the 2004 document. The GINA reports are available on www.ginasthma.org
- British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2003 Feb;58 Suppl 1(Suppl 1):i1-94. doi: 10.1136/thorax.58.suppl_1.1i. No abstract available.
- National Institutes of Health. Global strategy for asthma management and prevention. Bethesda (MD): Global Initiative for Asthma (GINA), National Institutes of Health, 2002 Feb. Publication no. 02-3659
- Dolovich MA, MacIntyre NR, Anderson PJ, Camargo CA Jr, Chew N, Cole CH, Dhand R, Fink JB, Gross NJ, Hess DR, Hickey AJ, Kim CS, Martonen TB, Pierson DJ, Rubin BK, Smaldone GC. Consensus statement: aerosols and delivery devices. American Association for Respiratory Care. Respir Care. 2000 Jun;45(6):589-96. No abstract available. Erratum In: Respir Care. 2000 Nov;45(11):1416.
- ICH topic E9 statistical principles for clinical trials - Note for guidance on statistical principles for clinical trials (CPMP/ICH/363/96).
- Frey U, Stocks J, Coates A, Sly P, Bates J. Specifications for equipment used for infant pulmonary function testing. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/ American Thoracic Society. Eur Respir J. 2000 Oct;16(4):731-40. doi: 10.1034/j.1399-3003.2000.16d28.x.
- Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir Med. 2000 May;94(5):496-500. doi: 10.1053/rmed.1999.0767.
- Global Initiative for Chronic Obstructive Lung Disease, Global Strategy for the Diagnosis, Management and Prevention of Cronic Obstructive Pulmonary Disease (Updated 2009)
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.